This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MarketVIEW: Meningococcus Serogroup B Vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

MarketVIEW: Meningococcus serogroup B vaccines

With the introduction of vaccines to prevent invasive meningococcal disease due serogroups ACWY, serogroup B now remains a major contributor to current disease burden, especially in Europe where it accounts for >50% of cases. Outer membrane vesicle (OMV) based vaccines have been used successfully to tackle clonal epidemics most recently in New Zealand and Normandy, however, these vaccines are strain specific and have limited utility on a global scale. Novartis and Pfizer vaccines are currently developing broader acting protein based vaccines, the former (4CmenB) is current undergoing registration in the EMA region. 

This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of new menB vaccines to 2030. The product contains three forecast models (LO, BASE, HI) which examine different adoption scenarios across 40 countries. Detailed coverage of Novartis (4CMenB) and Pfizer (rLP2086) is included with a focus on development history to date and coverage of latest cost effectiveness issues. Other novel menB vaccine approaches are discussed. 

This product is an ideal source of analysis for those wishing to assess the field of new meningococcal vaccines. 

THIS PRODUCT IS A EXECUTIVE PRESENTATION + 3 MODELS Contents – Executive presentation (MS PowerPoint based)Author's noteExecutive summaryCommercial model – key outputsTotal available global market to 2030: menB vaccine(s)menB vaccine: available market (<1 yrs) to 2030>menB vaccine: available market (1-5 yrs) to 2030menB vaccine: available market (11 - 18 yrs) to 2030menB vaccine: country adoption groupings (BASE) to 2030menB vaccine: early adopter MCC countries (BASE) to 2030menB vaccine: region summary (2018) - base scenarioNovartis Vaccines revenues per scenario to 2030Pfizer Vaccines revenues per scenario to 2030Disease background and latest epidemiologyImportance of serogroup BN. meningitidis dominant serotype(s) per regionN. meningitidis % serotype per regionGlobal ranking of N. meningitidis (all) incidenceGlobal ranking of N. meningitidis (serogroup B) incidenceUS - N. meningitidis incidence: serogroup distribution by ageUS - N. meningitidis incidence: by year 1997 – 2009Serogroup B: importance of global strainsImportance of meningococcal carriageDiscussion of meningococcal serogroup C vaccinationCase study for serogroup B?N. meningitidis incidence (EU), 1999 – 2006N. meningitidis (all) and serogroup C incidence (EU), 1999Serogroup C vaccination impact on EU incidence: 1999-2006Serogroup C vaccination impact on incidence – UKGlobal Men C conjugate vaccine programsGlobal Men A/C conjugate vaccine programsGlobal Men ACWY conjugate vaccine programsMeningococcal serogroup B vaccine: modelling commercial potentialOverall modeling rationaleSerogroup B epidemiology: methodology usedSerogroup B vaccine: rationale for country inclusionSerogroup B vaccine: Predicted early adopter countriesSerogroup B vaccine: Predicted later adopter countriesSerogroup B vaccine: Predicted limited/or no adoption countriesSerogroup B vaccine: proposed indicationsSerogroup B vaccine: modeling methodologyEarly adopter countries: vaccine uptake scenariosAll other countries: vaccine uptake scenariosCoverage level assumptions: 1-5 yrs (early adopters)Coverage level assumptions: 1-5 yrs (later adopters)Coverage level assumptions: 11-18 yrs (early adopters)Coverage level assumptions: 11-18 yrs (later adopters)Coverage level assumptions: USA (all ages)UK cost effectiveness analysis: overviewUK cost effectiveness analysis: direct protection modelUK cost effectiveness analysis: alternative strategiesUK cost effectiveness analysis: conclusionsSerogroup B vaccine - pricing scenariosSerogroup B vaccine – vaccinology and summary of major competitor programsTimeline of serogroup B vaccine development progressThe challenge of developing a serogroup B vaccineNew Zealand: impact of serogroup B OMV vaccineIssues with OMV vaccinesA new serogroup B vaccine - which protein antigens?Surface proteins of Neisseria meningitidisReview of selected major protein antigensFocus on Factor H binding protein (fHbp)4CMenB: Novartis Vaccines - vaccine components4CMenB: Novartis Vaccines - late development history4CMenB: Phase III data in infants4CMenB: summary of late stage development program4CMenB: coverage prediction UKBivalent rLP2086: Pfizer - vaccine componentsrLP2086: Pfizer Vaccines - strain poolPhylogenetic tree of fHBP/LP2086 variantsrLP2086: bactericidal activityrLP2086: Pfizer Vaccines - development historyrLP2086: Pfizer Vaccines - B1971005rLP2086: summary of late stage development program (Nov 11)rLP2086: Pfizer Vaccines - B1971009Pfizer versus Novartis vaccines approachesSurrogate markers of protection: key issues and challengesmenB vaccine(s): R&D pipeline / other approachesAppendix I – back up and source materialUK NHS immunization statistics, England 2010-2011BibliographyDisclaimerAbout VacZine AnalyticsPAGES: 110 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

***NOTE*** - there are 3 models (LO, BASE & Hi scenarios) each with ~ 90 individual sheets

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs